Triumph Financial Declares Quarterly Dividend for Series C Preferred Stock
August 30, 2025 - 04:13
DALLAS, Aug. 29, 2025 -- Triumph Financial, Inc. has announced a significant quarterly cash dividend for its 7.125% Series C Fixed-Rate Non-Cumulative Perpetual Preferred Stock. The Company’s Board of Directors has declared a dividend of $17.81 per share, which will be distributed to holders of depositary shares, each representing a 1/40th interest in a share of the preferred stock.
For investors holding depositary shares, this translates to a payment of $0.44525 per depositary share. The upcoming dividend is scheduled to be paid on September 15, 2025, marking another step in the Company’s commitment to providing value to its shareholders.
This announcement reflects Triumph Financial's ongoing efforts to maintain strong financial health and shareholder returns. Investors are encouraged to stay informed about future dividends and financial updates as the Company continues to navigate the evolving market landscape.
MORE NEWS
June 3, 2026 - 07:37
Japan finance minister says ready to respond appropriately on forexTOKYO, June 3 - Japanese Finance Minister Satsuki Katayama stated on Wednesday that the government is prepared to take appropriate measures in the foreign exchange market, issuing a fresh warning...
June 2, 2026 - 17:28
Thrifts & Mortgage Finance Stocks Q1 Results: Benchmarking Franklin BSP Realty Trust (NYSE:FBRT)The close of earnings season offers a useful moment to check in on how different sectors are navigating the current economic climate. For investors keeping an eye on thrifts and mortgage finance...
June 2, 2026 - 05:00
HPE expects to achieve 2028 financial targets this year after record quarter on AI boomHewlett Packard Enterprise reported record revenue for its second fiscal quarter on Monday, driven by surging demand for AI data center infrastructure. The strong performance has led the company to...
June 1, 2026 - 02:50
This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First QuarterA recent $5.5 million executive departure at Wave Life Sciences has drawn scrutiny following the company`s disappointing first-quarter performance. The clinical-stage biotech, which develops...